Nikhil Prasad Fact checked by:Thailand Medical News Team Feb 06, 2025 1 month, 3 days, 4 hours, 45 minutes ago
Medical News: A New Era in Breast Cancer Treatment
Breast cancer remains one of the most common cancers worldwide, and while advances in treatment have significantly improved survival rates, many therapies come with harsh side effects. To address this, researchers from the University of Texas Rio Grande Valley, Case Western Reserve University, and the MetroHealth Cancer Institute are exploring how molecular profiling can help reduce unnecessary toxic treatments while maintaining effectiveness.
Molecular Profiling and Reducing Toxic Therapy in Breast Cancer
This
Medical News report highlights how precision medicine is revolutionizing breast cancer therapy by helping doctors tailor treatments to individual patients. The goal is to minimize toxic side effects and financial burdens while ensuring that patients receive the most effective care possible.
The Shift Toward Personalized Treatment
Traditional breast cancer treatment often involves surgery, chemotherapy, and radiation therapy. While these methods have saved countless lives, they also bring long-term side effects that impact patients’ quality of life. Researchers have been studying how molecular profiling can allow some patients to avoid aggressive treatments that may not be necessary for their specific cancer type.
Molecular profiling is a technique that analyzes the genetic and biological characteristics of a tumor. This provides doctors with a clearer understanding of the cancer’s behavior, allowing them to determine whether a patient requires intensive therapy or if a less aggressive approach would be just as effective.
Key Findings in Molecular Profiling
Several studies have demonstrated that molecular profiling can help doctors make more informed decisions about breast cancer treatment. One of the key findings is that not all breast cancer patients require chemotherapy. For example, the TAILORx trial found that patients with hormone receptor-positive, HER2-negative breast cancer and a low genomic recurrence score could safely avoid chemotherapy without compromising their survival rates. Instead, they could be treated with endocrine therapy alone.
Another significant study, the MINDACT trial, used the MammaPrint genomic test to identify patients who were at low risk of recurrence. Even if traditional clinical assessments suggested chemotherapy, molecular profiling helped some patients safely skip this treatment. This approach spares many women from unnecessary chemotherapy-related side effects, such as fatigue, nausea, hair loss, and long-term heart damage.
In radiation therapy, molecular profiling is also helping refine treatment strategies. Trials such as LUMINA and DEBRA have shown that patients with specific tumor profiles may not need radiation therapy after surgery, reducing the risk of radiation-induced side effects while maintaining effective cancer control. The DCISionRT test, which predicts the benefit of radiation therapy for patients with ductal carcinoma in situ (DCIS), has further supported this trend toward personalized treatment.
r />
Expanding the Role of Genomic Testing
Molecular profiling has also been instrumental in identifying patients who will benefit from targeted therapies instead of traditional chemotherapy. Tests such as Oncotype DX, Prosigna, EndoPredict, and FoundationOne CDx analyze tumor genetics to guide treatment decisions.
For instance, Oncotype DX evaluates 21 genes to determine a patient’s risk of recurrence, helping doctors decide whether chemotherapy is necessary. Prosigna, based on the PAM50 gene signature, classifies tumors into subtypes and estimates the likelihood of recurrence over 10 years. FoundationOne CDx, a more comprehensive genomic profiling tool, examines over 300 genes to identify specific mutations that can be targeted with precision therapies.
Another exciting development is the use of liquid biopsies, such as Guardant360, which analyze circulating tumor DNA from blood samples. This less invasive approach allows real-time monitoring of a tumor’s response to treatment, enabling doctors to adjust therapies as needed without requiring repeated tissue biopsies.
Implications for the Future of Cancer Care
As molecular profiling continues to evolve, it is expected to play a growing role in breast cancer management. Clinical trials are now focusing on integrating genomic data into routine care, helping doctors make better treatment decisions for their patients. Researchers are also exploring ways to use molecular profiling in immunotherapy, further expanding personalized treatment options.
However, challenges remain. One of the biggest barriers is the cost of genomic testing, which may not be covered by all insurance plans. Additionally, the complexity of interpreting genomic data requires ongoing education for healthcare providers to ensure they can effectively use these tools in clinical practice.
Conclusion
The shift toward personalized medicine in breast cancer treatment is transforming how patients receive care. Molecular profiling enables doctors to identify which patients can safely avoid toxic treatments while ensuring those who need aggressive therapy receive the best possible care. By leveraging genomic data, oncologists can offer a more tailored approach that balances effectiveness with quality of life.
As research continues, more breast cancer patients will benefit from treatment strategies designed specifically for their unique tumor profiles. While challenges exist, the potential of molecular profiling to improve patient outcomes while reducing unnecessary toxicity is undeniable. The future of breast cancer treatment lies in precision medicine, and molecular profiling is leading the way.
The study findings were published in the peer-reviewed International Journal of Molecular Sciences.
https://www.mdpi.com/1422-0067/26/3/1332
For the latest on Breast Cancer, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/monensin-shows-potential-to-inhibit-triple-negative-breast-cancer-growth
https://www.thailandmedical.news/news/ubr2-in-triple-negative-breast-cancer-offers-new-hope-for-immunotherapy
https://www.thailandmedical.news/news/new-hope-for-breast-cancer-involving-triggering-necroptosis-using-a-phytochemical-from-eomecon-chionantha
https://www.thailandmedical.news/articles/cancer
Share
Tweet
Share
